Sofosbuvir plus Ribavirin for the Treatment of Russian Patients with Chronic HCV Genotype 1 or 3 Infection

被引：0

作者：

Chulanov, Vladimir ^{[1
]}

Zhdanov, Konstantin ^{[2
]}

Kersey, Kathryn ^{[3
]}

Zhu, Yanni ^{[3
]}

Massetto, Benedetta ^{[3
]}

Zhuravel, Sergey ^{[4
]}

Romanova, Svetlana ^{[5
]}

Nurmukhametova, Elena ^{[6
]}

Morozov, Viacheslav ^{[7
]}

Kozhevnikova, Galina ^{[1
]}

Gogova, Larisa ^{[8
]}

Geyvandova, Natalia ^{[9
]}

Gankina, Natalia ^{[10
]}

Chesnokov, Evgenii ^{[11
]}

Burnevich, Eduard Z. ^{[12
]}

Bessonova, Elena ^{[13
]}

Abdurakhmanov, Djamal ^{[14
]}

Brainard, Diana M. ^{[3
]}

McHutchison, John G. ^{[3
]}

Bakulin, Igor G. ^{[15
]}

Isakov, Vasily ^{[16
]}

机构：

[1] Cent Res Inst Epidemiol, Moscow, Russia

[2] SM Kirov Mil Med Acad, St Petersburg, Russia

[3] Gilead Sci Inc, Foster City, CA 94404 USA

[4] Sci Res Inst Emergency Care, Moscow, Russia

[5] Ctr Prevent & Control AIDS & Infect Dis, St Petersburg, Russia

[6] Infect Clin Hosp 1, Moscow, Russia

[7] Med Co Hepatolog LLC, Samara, Russia

[8] Russian Acad Sci, Cent Clin Hosp, Moscow, Russia

[9] Stavropol Reg Clin Ctr Special Med Care, Stavropol, Russia

[10] Krasnoyarsk Reg Ctr Prevent & Control AIDS & Infe, Krasnoyarsk, Russia

[11] Consultat & Diagnost Ctr, Tyumen, Russia

[12] City Clin Hosp 24, Moscow, Russia

[13] Sverdlovsk Reg Clin Hosp 1, Ekaterinburg, Russia

[14] IM Sechenov First Moscow State Med Univ, Moscow, Russia

[15] Moscow Cent Sci Inst Gastroenterol, Moscow, Russia

[16] Russian Acad Med Sci, Inst Nutr, Moscow 109801, Russia

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

982

引用

页码：676A / 677A

页数：2

共 50 条

[21] Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C
Satsangi, Sandeep
Mehta, Manu
Duseja, Ajay
Taneja, Sunil
Dhiman, Radha K.
Chawla, Yogesh
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (04) : 859 - 863
[22] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
G. Shiha
R. Soliman
M. ElBasiony
A. A. Hassan
N. N. H. Mikhail
Hepatology International, 2018, 12 : 339 - 347
[23] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Shiha, G.
Soliman, R.
ElBasiony, M.
Hassan, A. A.
Mikhail, N. N. H.
HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 339 - 347
[24] Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
Pianko, S.
Cooper, C.
Brown, A.
Forton, D.
Nahass, R.
George, J.
Barnes, E.
Brainard, D.
Massetto, B.
Lin, M.
Mchutchinson, J.
Subramanian, G. M.
Agarwal, K.
Foster, G.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 90 - 90
[25] Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Charlton, Michael
Everson, Gregory T.
Flamm, Steven L.
Kumar, Princy
Landis, Charles
Brown, Robert S., Jr.
Fried, Michael W.
Terrault, Norah A.
O'Leary, Jacqueline G.
Vargas, Hugo E.
Kuo, Alexander
Schiff, Eugene
Sulkowski, Mark S.
Gilroy, Richard
Watt, Kymberly D.
Brown, Kimberly
Kwo, Paul
Pungpapong, Surakit
Korenblat, Kevin M.
Muir, Andrew J.
Teperman, Lewis
Fontana, Robert J.
Denning, Jill
Arterburn, Sarah
Dvory-Sobol, Hadas
Brandt-Sarif, Theo
Pang, Phillip S.
McHutchison, John G.
Reddy, K. Rajender
Afdhal, Nezam
GASTROENTEROLOGY, 2015, 149 (03) : 649 - 659
[26] Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin
Agarwal, Kosh
Schultz, Michael
Pianko, Stephen
Bank, Leslie
Collier, Jane
George, Jacob
Priest, Matthew
Ryder, Stephen D.
Burman, Blaire E.
Cheent, Kuldeep
Cramp, Matthew
Forton, Daniel M.
Leggett, Barbara A.
MacQuillan, Gerry C.
Ramji, Alnoor
Richardson, Paul
Ryan, Michael J.
Stace, Nigel
Zekry, Amany
Zogg, Donald L.
Barnes, Eleanor
Brainard, Diana M.
Massetto, Benedetta
Chen, Frances
McHutchison, John G.
Subramanian, Mani
Yoshida, Eric M.
Foster, Graham R.
HEPATOLOGY, 2016, 64 : 455A - 456A
[27] Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
Ruane, Peter J.
Ain, Dani
Stryker, Richard
Meshrekey, Raymond
Soliman, Mina
Wolfe, Peter R.
Riad, Joseph
Mikhail, Sameh
Kersey, Kathryn
Jiang, Deyuan
Massetto, Benedetta
Doehle, Brian
Kirby, Brian J.
Knox, Steven J.
McHutchison, John G.
Symonds, William T.
JOURNAL OF HEPATOLOGY, 2015, 62 (05) : 1040 - 1046
[28] Compare the Efficacy of Sofosbuvir Plus Ribavirin Verus Sofosbuvir Plus Daclatasvir in Patients with Chronic C Hepatitis Genotype 2 Infection
Chang, Kuo-Chin
Hu, Tsung-Hui
Chen, Chien Hung
Wang, Jing-Houng
HEPATOLOGY, 2018, 68 : 586A - 586A
[29] An integrated safety analysis of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection
Landis, Charles S.
Nelson, David R.
Sulkowski, Mark S.
Ruane, Peter J.
Mills, Anthony M.
Poordad, Fred
Wyles, David L.
Bhore, Rafia
Ackerman, Peter
Rana, Khurram
Swenson, Eugene S.
Noviello, Stephanie
HEPATOLOGY, 2015, 62 : 565A - 565A
[30] Ledipasvir/Sofosbuvir in the Treatment of Japanese Patients with Chronic HCV Genotype 2 Infection
Asahina, Yasuhiro
Itoh, Yoshito
Ueno, Yoshiyuki
Matsuzaki, Yasushi
Takikawa, Yasuhiro
Yatsuhashi, Hiroshi
Genda, Takuya
Ikeda, Fusao
Matsuda, Takuma
Huang, K. C.
Massetto, Benedetta
Osinusi, Anu O.
Brainard, Diana M.
McHutchison, John G.
Kawada, Norifumi
Enomoto, Nobuyuki
HEPATOLOGY, 2017, 66 : 638A - 638A

← 1 2 3 4 5 →